AAIC 2025 Abstract
Meaningful Clinical Impact of ABvac40 in Early‐Stage Alzheimer’s Disease: Results from the AB1601 Phase 2 Study
Trial in peopleInterventions
Abstract
Background: ABvac40 is an investigational vaccine targeting Aβ40 for the treatment of Alzheimer’s disease (AD). Aβ40 plays a significant role in several pathological processes of AD, especially concerning amyloid deposition in blood vessels.
